Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Interventions
DRUG

DIRITHROMYCIN 500 MG ENTERIC COATED TABLET

DRUG

DYNABAC 250 MG ENTERIC COATED TABLET

Trial Locations (1)

11941

Arab Pharmaceutical industry Consulting/ Pharmaceutical Research Unit, Amman

All Listed Sponsors
collaborator

Abdi Ibrahim Ilac San. ve Tic A.S.

INDUSTRY

lead

Pharmaceutical Research Unit, Jordan

OTHER